KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin and blood, respectively, demonstrating strong translation ...

Bullous pemphigoid (BP) is the most common autoimmune blistering disease seen in older adults. A recent meta-analysis evaluating the safety and efficacy of dupilumab in patients with moderate to ...

DEAR DR. ROACH: I am a 73-year-old woman who is in otherwise good health, but I was diagnosed with bullous pemphigoid, a rare autoimmune disease, in January 2022. I have been treated by three ...

Patients with cancer often require specialised care at centres located far from their residence. During the COVID-19 pandemic, telemedicine has rapidly gained ground as a way to ease system pressures ...

Bullous pemphigoid (BP) is an autoimmune disorder that mainly affects older adults. The condition causes your immune system to attack proteins that hold the layers of your skin together. This damages ...

TUESDAY, June 24, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on ...

The FDA approved dupilumab (Dupixent) as the first targeted drug for bullous pemphigoid, a rare blistering skin disease that largely affects elderly patients, drugmakers Sanofi and Regeneron announced ...

The FDA is expected to decide on treatments for bullous pemphigoid, hereditary angioedema, HIV PrEP, ovarian cancer, and RSV. The FDA is reviewing the BLA for clesrovimab to prevent respiratory ...

The FDA is reviewing the BLA for clesrovimab to prevent respiratory syncytial virus (RSV) disease in infants during their first RSV season. Clesrovimab is an extended half-life RSV fusion glycoprotein ...

More than 90 tornadoes have been reported across 10 states. Relentless, life-threatening weather conditions continued into Sunday across multiple states, including the threat of severe flooding in ...